Translation 051

Par'd PC 1 05 MAY 2005

PATENT COOPERATION TREATY

U5 MAY 2005 PCT/JP2003/014454

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	,			
ONF-4776PCT	FOR FURTHER	ACTION	See Form PCT/IPEA/416	
International application No.		date (day/month/year)	Priority date (day/month/year)	
PCT/JP2003/014454		2003 (13.11.2003)	14 November 2002 (14.11.2002)	
International Patent Classification (IPC) or no A61K 45/00, 31/426, 31/499, 31/426	ational classification of /517, A61P 19/00, 2	and IPC 25/00, 43/00		
Applicant O	NO PHARMACE	EUTICAL CO., LTI	Э.	
This report is the international prelin Authority under Article 35 and trans	ninary examination re	port, established by this t according to Article 36	International Preliminary Examining	
2. This REPORT consists of a total of	6 sheet	s, including this cover sl	heet.	
3. This report is also accompanied by A	NNEXES, comprisin	g:		
a. (sent to the applicant and	to the International B	ureau) a total of	sheets, as follows:	
Administrative Ins	tructions).	adiorized by this Author	en amended and are the basis of this report rity (see Rule 70.16 and Section 607 of the	
sheets which super beyond the disclos Supplemental Box.		ut which this Authority al application as filed, a	considers contain an amendment that goes s indicated in item 4 of Box No. I and the	
b. (sent to the International	al Bureau only) a	total of (indicate typ	e and number of electronic carrier(s)) and/or tables related thereto, in computer Sequence Listing (see Section 802 of the	
4. This report contains indications relations	ng to the following ite	ems:		
Box No. I Basis of the rep	ort			
Box No. II Priority				
Box No. III Non-establishm	ent of opinion with re	gard to novelty, inventive	ve step and industrial applicability	
Box No. IV Lack of unity of	invention			
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
Box No. VI Certain docume				
Box No. VII Certain defects in the international application				
Box No. VIII Certain observat	ions on the internatio	nal application		
Date of submission of the demand		Date of completion of	this report	
12 May 2004 (12.05.2004)		19 Nov	ember 2004 (19.11.2004)	
Name and mailing address of the IPEA/JP		Authorized officer		
acsimile No.		Telephone No.		



INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

Box No. I Basis of the report 1. With regard to the language, this report is based on the international application in the language in which it otherwise indicated under this item. This report is based on translations from the original language into the following language which is language of a translation furnished for the purpose of:	was filed, unless
This report is based on translations from the original language into the following language which is language of a translation furnished for the purpose of:	was filed, unless
The purpose of:	
	,
international search (under Rules 12.3 and 23.1(b))	
publication of the international application (under Rule 12.4)	
international preliminary examination (under Rules 55.2 and/or 55.3)	
2. With regard to the elements of the international application, this report is based on (replacement sheet furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report and are not annexed to this report): The international application as originally filed/furnished the description: pages pages* received by this Authority on pages* pages pages pages pages pages , as originally filed/furnished the claims: pages received by this Authority on as amended (together with any state) pages* received by this Authority on	iginally filed/furnished
pages* received by this Authority on	
the drawings:	
pages, as ori	iginally filed/furnished
received by this Authority on	
received by this Authority on	
a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing. 3. The amendments have resulted in the cancellation of: the description, pages the claims Nos	
the drawings shoots (5 -	
the drawings, sheets/figs	
the sequence listing (specify):	
any table(s) related to sequence listing (specify):	
This report has been established as if (some of) the amendments annexed to this report and listed belonged, since they have been considered to go beyond the disclosure as filed, as indicated in the Su (Rule 70.2(c)). the description, pages the claims, Nos. the drawings, sheets/figs the sequence listing (specify): any table(s) related to sequence listing (specify):	ow had not been upplemental Box
* If item 4 applies, some or all of those sheets may be marked "superseded."	




INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/JP2003/014454

Box N	o. III Non-establishment of opi	ion with regard to novelty, inventive step and industrial applicability
The q		ion annears to be revel to it.
	the entire international applicat	on.
\boxtimes	claims Nos	13
\boxtimes	ause: the said international application relate to the following subject in See supplemental s	latter which does not require an international preliminary examination (consist)
	the description, claims or drawing are so unclear that no meaning for	gs (indicate particular elements below) or said claims Nos opinion could be formed (specify):
	the claims, or said claims Nos by the description that no meaning no international search report has	gful opinion could be formed. been established for said claims Nos13
	the nucleotide and/or amino acid Administrative Instructions in tha	equence listing does not comply with the standard provided for in Annex C of the
	the written form	has not been furnished
		does not comply with the standard
	the computer readable form	has not been furnished
		does not comply with the standard
	the tables related to the nucleotide the technical requirements provide	and/or amino acid sequence listing, if in computer readable form only, do not comply with I for in Annex C-bis of the Administrative Instructions.
	see Supplemental Box for further of	
rm PCT	C/IPEA/409 (Box No. III) (January)	204)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT



Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: III. 1.

Claim 13 pertains to methods for treatment of the human body by therapy, and thus relates to subject matter which does not require international preliminary examination by this International Preliminary Examining Authority, under the provisions of PCT Article 34(4)(a)(i) and PCT Rule 67.1(iv).

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/JP 03/14454

1.	Statement			
	Novelty (N)	Claims	1-12, 14	YES
		Claims		NO
	Inventive step (IS)	Claims	1-12, 14	YES
		Claims		NO
	Industrial applicability (IA	(IA) Claims	1-12, 14	YES
		Claims		— NO
	Citations and explanation	ons		
٠	Document 1:	JP 2000-344666 December 2000	A (Sankyo Co., ltd.), 12	
	Document 2:	WO 95/01096 A1 January 1995	(Howard K. Shapiro), 12	
	Document 3:		(Welfide Corp,), 13 Dece	mber

Document 4: JP 2001-199890 A (Welfide Corp,), 24 July

2001

Document 5: EP 1146337 Al (Welfide Corp,), 17 October 2001

Claims 1-12, 14

The inventions set forth in claims 1-12 and 14 in the present application are not disclosed or suggested in documents 1-5 above, cited in the international search report, and are novel and involve an inventive step.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/JP 03/14454

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 1-12 and 14

The above claims in the present application relate to prophylactic and/or therapeutic agents for vertebral canal stenosis in which the active ingredient is a compound defined by a desired property, as an "aldose reductase inhibiting compound", and the scope of the above claims in the present application includes all compounds having such a property. However, only a very small fraction of the claimed compounds are supported by the description in the sense of PCT Article 6 and disclosed in the sense of PCT Article 5.

The above claims in the present application also do not fulfil the condition of clarity in PCT Article 6, since it is impossible from reference to general knowledge of the art at the time of filing to specify the scope of compounds having the property of being an "aldose reductase inhibiting compound".